Ignite Creation Date:
2024-05-06 @ 1:50 AM
Last Modification Date:
2024-10-26 @ 11:10 AM
Study NCT ID:
NCT01914809
Status:
UNKNOWN
Last Update Posted:
2020-09-25
First Post:
2013-07-11
Brief Title:
Micro Array Analysis in Preeclampsia
Sponsor:
Assistance Publique Hopitaux De Marseille
Organization:
Assistance Publique Hopitaux De Marseille
Study Overview
Official Title:
Micro Array Analysis in Preeclampsia
Status:
UNKNOWN
Status Verified Date:
2020-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Preeclampsia is a frequent pathology His etiology is doubtful
Targets
The study target is to identify a risk of preeclampsia group obtained with transcriptom analysis from circulating peripheric cells
Design
Multidisciplinary study Gynaecology-Obstetric Immunology North CIC
The study of the transcriptional history of peripheral blood cells of 2patients groups
A patient group with a preeclampsia before 34 SA
A patient group with a normal pregnancy paired on main confusion factors Blood sampling will be collected at the diagnosis and 8 weeks after delivery
Results and perspectives
Obtain a transcriptionnal signature of preeclampsia
To identify new mechanism of the disease
Identification of a specific transcriptom analysis with the comparison after delivery For long-term the target is to identify risk patient in order to conduct easily preventive clinical trials in preeclamsia primary prevention and to consider a specific follow-up for risk patients
Targets
The study target is to identify a risk of preeclampsia group obtained with transcriptom analysis from circulating peripheric cells
Design
Multidisciplinary study Gynaecology-Obstetric Immunology North CIC
The study of the transcriptional history of peripheral blood cells of 2patients groups
A patient group with a preeclampsia before 34 SA
A patient group with a normal pregnancy paired on main confusion factors Blood sampling will be collected at the diagnosis and 8 weeks after delivery
Results and perspectives
Obtain a transcriptionnal signature of preeclampsia
To identify new mechanism of the disease
Identification of a specific transcriptom analysis with the comparison after delivery For long-term the target is to identify risk patient in order to conduct easily preventive clinical trials in preeclamsia primary prevention and to consider a specific follow-up for risk patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2010-04 | OTHER | AP HM | None |